The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Open accessAbstract
Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.Methods In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.Findings Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.Interpretation Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Initial results demonstrated a 31% objective response rate and 69% demonstrated at least 12 weeks of stable disease [78].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [78]
In the citing paper
“The Checkmate-142 phase II study demonstrated the effectiveness of nivolumab in previously treated MSI-H mCRC patients [84].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Upon examining the subgroup analysis of this study, it was observed that patients without RAS or BRAF mutations achieved a 41% objective response rate with nivolumab. In comparison, the rate was 27% in RAS mutant patients.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53,54,55,56].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Nivolumab, an anti-PD1 monoclonal antibody (moAb), has been utilized since 1 August 2017, for MSI-H/dMMR mCRC, as evidenced by the CheckMate 142 study [54].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“The CHECKMATE 142 study reported that Nivolumab could provide a durable response in patients with dMMR/MSI-H metastatic colorectal cancer, proposing Nivolumab as a new treatment option in these patients [117].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cited by
Sorted by citations
Items 701–800 of 1,005
Sun, L., Huang, S., Li, D., Ye, M., Wang, Y., & Wu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754881 · Cited by 40
Liu, F., Dai, Z., Cheng, Q., Xu, L., Huang, L., Liu, Z., Li, X., Wang, N., Wang, G., Wang, L., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121485 · Cited by 40
Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of Care
Grothey, A. F. (2020) · New England Journal of Medicine · doi:10.1056/nejme2031294 · Cited by 39
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
Rocha, L. S. D. S., & Riechelmann, R. P. (2018) · Clinics · doi:10.6061/clinics/2018/e542s · Cited by 39
Larsen, S. G., Goscinski, M. A., Dueland, S., Steigen, S. E., Hofsli, E., Torgunrud, A., Lund‐Iversen, M., Dagenborg, V. J., Flatmark, K., & Sorbye, H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01620-6 · Cited by 39
Wang, Y., Zou, J., Li, Y., Jiao, X., Wang, Y., Zhuo, N., Gao, M., Gong, J., Li, J., Zhang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.987568 · Cited by 39
DNA mismatch repair in cancer immunotherapy
Guan, J., & Li, G. (2023) · NAR Cancer · doi:10.1093/narcan/zcad031 · Cited by 41
Advancements in clinical research and emerging therapies for triple-negative breast cancer treatment
Xu, L., Xu, P., Wang, J., Ji, H., Zhang, L., & Tang, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177202 · Cited by 42
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
Wakabayashi, G., Lee, Y., Luh, F., Kuo, C.-N., Chang, W., & Yen, Y. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0588-8 · Cited by 39
Zhang, P., Liu, M., Cui, Y., Zheng, P., & Liu, Y. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa180 · Cited by 39
Campbell, B. B., Galati, M. A., Stone, S. C., Riemenschneider, A. N., Edwards, M., Sudhaman, S., Siddaway, R., Komosa, M., Nunes, N. M., Nobre, L. F., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1050 · Cited by 40
Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Guarini, C., Grassi, T., Pezzicoli, G., & Porta, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136813 · Cited by 41
LTF Regulates the Immune Microenvironment of Prostate Cancer Through JAK/STAT3 Pathway
Zhao, Q., Cheng, Y., & Xiong, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692117 · Cited by 38
The Immune Landscape of Colorectal Cancer
Mezheyeuski, A., Micke, P., Martín-Bernabé, A., Backman, M., Hrynchyk, I., Hammarström, K., Ström, S., Ekström, J., Edqvist, P.-H. D., Sundström, M., et al. (2021) · Cancers · doi:10.3390/cancers13215545 · Cited by 39
PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
Sclafani, F. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30512-0 · Cited by 39
Chen, M., Jiang, M., Wang, X., Shen, L., & Li, J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2125799 · Cited by 38
Yu, Y., Shan, N., Li, L., Zhu, Y., Lin, L., Mao, C., Hu, T., Xue, X., Su, X., Shen, X., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03386-7 · Cited by 40
Wang, C., Liu, T.-C., Lai, P.-J., Muzakky, H., Wang, Y., Yu, M.-H., Wu, C.-H., & Chao, T. (2024) · Medical Image Analysis · doi:10.1016/j.media.2024.103372 · Cited by 41
Chu, J. N., Choi, J., Ostvar, S., Torchia, J. A., Reynolds, K. L., Tramontano, A. C., Gainor, J. F., Chung, D. C., Clark, J. W., & Hur, C. (2018) · Cancer · doi:10.1002/cncr.31795 · Cited by 38
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
Li, Y., Liu, J., Gao, L., Liu, Y., Meng, F., Li, X., & Qin, F. X.-F. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.006 · Cited by 39
Mechanisms of Resistance to Checkpoint Blockade Therapy
Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 37
Sadeghlar, F., Vogt, A., Mohr, R. U., Mahn, R., van Beekum, K., Kornek, M., Weismüller, T. J., Branchi, V., Matthaei, H., Toma, M. I., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02746-x · Cited by 38
From APC to the genetics of hereditary and familial colon cancer syndromes
Olkinuora, A. P., Peltomäki, P., Aaltonen, L. A., & Rajamäki, K. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab208 · Cited by 41
Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Yang, W., Lei, C., Song, S., Jing, W., Jin, C., Gong, S., Tian, H., & Guo, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02299-8 · Cited by 40
Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma
Frizziero, M., Kilgour, E., Simpson, K., Rothwell, D. G., Moore, D. A., Frese, K. K., Galvin, M., Lamarca, Á., Hubner, R. A., Valle, J. W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3058 · Cited by 41
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37
Tan, E. S., & Şahin, İ. H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1886077 · Cited by 37
Song, Y., Huang, J., Liang, D., Hu, Y., Mao, B., Li, Q., Sun, H., Yang, Y., Zhang, J., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.549777 · Cited by 40
Obata‐Ninomiya, K., Carrion, S. D. J., Hu, A. K., & Ziegler, S. F. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl6960 · Cited by 37
Berrino, E., Aquilano, M. C., Valtorta, E., Amodio, V., Germano, G., Gusmini, M., Gizzi, K., Fenocchio, E., Sapino, A., Marsoni, S., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100012 · Cited by 37
Bao, X., Wang, D., Dai, X., Liu, C., Zhang, H., Jin, Y., Tong, Z., Li, B., Tong, C., Shan, X., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100987 · Cited by 38
Manzi, J. L. L., Hoff, C. O., Ferreira, R., Pimentel, A., Datta, J., Livingstone, A. S., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15113023 · Cited by 41
An Update on Colorectal Cancer
Xue, L., Williamson, A. J., Gaines, S., Andolfi, C., Paul-Olson, T., Neerukonda, A. R., Steinhagen, E. F., Smith, R. K., Cannon, L. M., Polite, B. N., et al. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.02.003 · Cited by 39
Morano, F., Corallo, S., Niger, M., Barault, L., Milione, M., Berenato, R., Moretto, R., Randon, G., Antista, M., Belfiore, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy197 · Cited by 38
Liu, S. T., Gönen, M., Stadler, Z. K., Weiser, M. R., Hechtman, J. F., Vakiani, E., Wang, T., Vyas, M., Joneja, U., Al-Bayati, M., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0114-7 · Cited by 37
Essakly, A., Loeser, H., Kraemer, M., Alakus, H., Chon, S., Zander, T., Buettner, R., Hillmer, A. M., Bruns, C. J., Schroeder, W., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.10.013 · Cited by 40
Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma
Ahmad-Nielsen, S. A., Nielsen, M. F. B., Mortensen, M. B., & Detlefsen, S. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152985 · Cited by 37
Colon cancer and immunotherapy—can we go beyond microsatellite instability?
Breakstone, R. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.03.08 · Cited by 39
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Lai, E., Liscia, N., Donisi, C., Mariani, S., Tolu, S., Pretta, A., Persano, M., Pinna, G., Balconi, F., Pireddu, A., et al. (2020) · Cancers · doi:10.3390/cancers12051214 · Cited by 37
Paredes, J. E., Zabaleta, J., Garai, J., Ji, P., Imtiaz, S., Spagnardi, M., Alvarado, J. I., Li, L., Akadri, M., Barrera, K., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01498 · Cited by 37
Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival
Alese, O. B., Zhou, W., Jiang, R., Zakka, K. M., Huang, Z., Okoli, C., Shaib, W. L., Akce, M., Diab, M., Wu, C. S.-Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.728076 · Cited by 37
Wang, Q., Xiao, B., Cheng, Y., Wu, A., Zhang, T., Wang, H., Zhang, X., Huang, W.-X., Tang, J., Wu, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.016 · Cited by 38
Martinelli, E., Cremolini, C., Mazard, T., Vidal, J., Virchow, I., Tougeron, D., Cuyle, P., Chibaudel, B., Kim, S. C. H., Ghanem, I., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100603 · Cited by 38
Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer
Hajj, J. E., Reddy, S., Verma, N., Huang, E. H., & Kazmi, S. M. A. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00927-2 · Cited by 36
Clifford, R. E., Govindarajah, N., Parsons, J. L., Gollins, S., West, N. P., & Vimalachandran, D. (2018) · British journal of surgery · doi:10.1002/bjs.10993 · Cited by 37
Chen, Q.-G., Zhang, L., Sun, F., Li, S., You, X.-H., Jiang, Y., Yang, W., Zhong, Q., Wang, X., & Ying, H. (2019) · Aging · doi:10.18632/aging.101864 · Cited by 37
Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients
Bai, W., Ma, J., Liu, Y., Liang, J., Wu, Y., Yang, X., Xu, E., Li, Y., & Xi, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2111 · Cited by 35
Ono, R., Nakayama, K., Nakamura, K., Yamashita, H., Ishibashi, T., Ishikawa, M., Minamoto, T., Razia, S., Ishikawa, N., Otsuki, Y., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153744 · Cited by 36
Loupakis, F., Maddalena, G., Depetris, I., Murgioni, S., Bergamo, F., Tos, A. P. D., Rugge, M., Munari, G., Nguyen, A., Szeto, C. W., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0788-5 · Cited by 37
Self-citationNext-generation sequencing for the management of sarcomas with no known driver mutations
Vyse, S., Thway, K., Huang, P. H., & Jones, R. L. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000741 · Cited by 36
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang, C., & Fakih, M. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1933940 · Cited by 36
Perspectives on Immunotherapy of Metastatic Colorectal Cancer
Dai, Y., Zhao, W., Yue, L., Dai, X., Rong, D., Wu, F., Gu, J., & Qian, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659964 · Cited by 37
Fanale, D., Corsini, L. R., Scalia, R., Brando, C., Cucinella, A., Madonia, G., Dimino, A., Filorizzo, C., Barraco, N., Bono, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103597 · Cited by 37
Hasegawa, H., Shitara, K., Takiguchi, S., Takiguchi, N., Ito, S., Kochi, M., Horinouchi, H., Kinoshita, T., Yoshikawa, T., Muro, K., et al. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01286-w · Cited by 37
Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer
Glass, E. B., Hoover, A., Bullock, K. K., Madden, M. Z., Reinfeld, B. I., Harris, W., Parker, D., Hufnagel, D. H., Crispens, M. A., Khabele, D., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09612-2 · Cited by 37
Nanodrugs Targeting T Cells in Tumor Therapy
Haist, M., Mailänder, V., & Bros, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912594 · Cited by 36
MSI colorectal cancer, all you need to know
Flecchia, C., Zaanan, A., Lahlou, W., Basile, D., Broudin, C., Gallois, C., Pilla, L., Karoui, M., Manceau, G., & Taı̈eb, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101983 · Cited by 40
Practice-changing updates in the adjuvant and metastatic setting
Puccini, A., & Lenz, H. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.185 · Cited by 36
Self-citationDeng, Z., Cui, L., Li, P., Ren, N., Zhong, Z., Tang, Z., Wang, L., Gong, J., Cheng, H., Guan, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04223-4 · Cited by 35
Immunotherapy-induced Hepatotoxicity: A Review
Cunha, T. D., Wu, G. Y., & Vaziri, H. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00105 · Cited by 37
Current clinical topics of Lynch syndrome
Tanakaya, K. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1282-7 · Cited by 35
Mucinous adenocarcinoma of the colon and rectum: A genomic analysis
Reynolds, I. S., O’Connell, E., Fichtner, M. W., McNamara, D. A., Kay, E. W., Prehn, J. H. M., Furney, S. J., & Burke, J. P. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25764 · Cited by 35
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 34
Zhang, Z., Cheng, S., Gong, J., Lu, M. S., Zhou, J., Zhang, X., Li, J., Shen, L., & Peng, Z. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.06.034 · Cited by 35
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35
Gastman, B., Agarwal, P. K., Berger, A., Boland, G. M., Broderick, S., Butterfield, L. H., Byrd, D. R., Fecci, P. E., Ferris, R. L., Fong, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001583 · Cited by 39
Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
Hwang, K., Yoon, J. H., Lee, J., & Lee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9010039 · Cited by 37
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 36
Jiao, X., Wei, X. L., Li, S., Liu, C. X., Chen, H., Gong, J., Li, J., Zhang, X., Wang, X., Peng, Z., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00172-5 · Cited by 36
Sumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 36
Pastor, D. M., & Schlom, J. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01085-z · Cited by 38
Farshbafnadi, M., Khoshbin, A. P., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107876 · Cited by 39
Osumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 38
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
Verdon, D. J., & Jenkins, M. R. (2021) · Cancers · doi:10.3390/cancers13164245 · Cited by 36
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 38
Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy.
Li, W.-Y., Wu, Z., Meng, W., Zhang, C.-T., Cheng, M.-Z., Chen, Y.-H., Zou, Y., Li, K.-J., Lin, S., Xiong, W., et al. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155976 · Cited by 29
Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer
Chuang, J., Tsai, H., Chen, P.-J., Chang, T., Su, W., Yeh, Y., Huang, C., & Wang, J. (2022) · Cells · doi:10.3390/cells11233744 · Cited by 34
Kelly, R. J., Bever, K. M., Chao, J., Ciombor, K. K., Eng, C., Fakih, M., Goyal, L., Hubbard, J. M., Iyer, R. V., Kemberling, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006658 · Cited by 36
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review
DeStefanis, R. A., Kratz, J. D., Emmerich, P. B., & Deming, D. A. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00430-6 · Cited by 34
Wang, Y., Chen, H., Jiao, X., Wu, L., Yang, Y., Zhang, J., Wu, L., Liu, C. X., Zhuo, N., Li, S., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02966-9 · Cited by 36
Moosavi, S. H., Eide, P. W., Eilertsen, I. A., Brunsell, T. H., Berg, K. C. G., Røsok, B. I., Brudvik, K. W., Bjørnbeth, B. A., Guren, M. G., Nesbakken, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00956-1 · Cited by 34
Spira, A. I., Wertheim, M. S., Kim, E. J.-H., Tan, B. R., Lenz, H., Nikolinakos, P. G., Rich, P. L., Jehl, G., Machl, A. W., Ito, R., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac254 · Cited by 34
Self-citationTakei, S., Tanaka, Y., Lin, Y.-T., Koyama, S., Fukuoka, S., Hara, H., Nakamura, Y., Kuboki, Y., Kotani, D., Kojima, T., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008210 · Cited by 35
Advani, S., & Kopetz, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25441 · Cited by 35
Self-citationTherapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 34
Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
Song, Y., Gu, Y., Hu, X., Wang, M., He, Q., & Li, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s324641 · Cited by 34
Current status and future perspective of immune checkpoint inhibitors in colorectal cancer
Zhou, C., Cheng, X., & Tu, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.023 · Cited by 35
Tan, X., Gong, L., Li, X., Zhang, X., Sun, J., Luo, X., Wang, Q., Chen, J., Xie, L., & Han, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112174 · Cited by 34
Vita, A. D., Vanni, S., Fausti, V., Cocchi, C., Recine, F., Miserocchi, G., Liverani, C., Spadazzi, C., Bassi, M., Gessaroli, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111564 · Cited by 34
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 36
Recent progress in cancer immunotherapy: Overview of current status and challenges
Darvishi, M., Tosan, F., Nakhaei, P., Manjili, D. A., Kharkouei, S. A., Alizadeh, A. M., Ilkhani, S., Khalafi, F., Zadeh, F. A., & Shafagh, S.-G. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154241 · Cited by 35
Wensink, G. E., Bond, M. J. G., Küçükköse, E., May, A. M., Vink, G. R., Koopman, M., Kranenburg, O., & Roodhart, J. M. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102174 · Cited by 35
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial
Coutzac, C., Bibeau, F., Abdelghani, M. B., Aparicio, T., Cohen, R., Coquan, E., Dubreuil, O., Evesque, L., Ghiringhelli, F., Kim, S. C. H., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.07.008 · Cited by 35
Saunders, M. P., Graham, J., Cunningham, D., Plummer, R., Church, D. N., Kerr, R. S., Cook, S., Zheng, S. S., Thangue, N. B. L., & Kerr, D. J. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100594 · Cited by 33
Zhuang, Y.-P., Zhou, H., Chen, H., Zheng, M.-Y., Liang, Y., Gu, Y.-T., Li, W., Qiu, W., & Zhou, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115040 · Cited by 34
Gallois, C., Landi, M., Taı̈eb, J., Sroussi, M., Saberzadeh-Ardestani, B., Cazelles, A., Lonardi, S., Bergamo, F., Intini, R., Maddalena, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3964 · Cited by 36
Self-citationNanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment
Lang, X., Wang, X., Han, M., & Guo, Y. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455213 · Cited by 36
Predictors of response to immunotherapy in colorectal cancer
González‐Montero, J., Rojas, C. I., & Burotto, M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae152 · Cited by 36
Chen, Q., Shen, M., Yan, M., Han, X., Mu, S., Li, Y., Luo, L., Wang, Y., Li, S., Li, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05518-8 · Cited by 34
Metadata
- Authors
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V., Cao, Z. A., Ledeine, J.-M., Maglinte, G. A., Kopetz, S., & André, T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Trials Ireland (IE)
- Allina Health (US)
- Istituto Oncologico Veneto (IT)
- USC Norris Comprehensive Cancer Center (US)
- Duke Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Belgium) (BE)
- Sorbonne Université (FR)
- Corresponding author
- Overman, Michael J
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 18
- Issue
- 9
- Pages
- 1182-1191
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC6207072
- OpenAlex
- W2739132742
- Cited by
- 2,836
- References
- 37
- Citations by year
- 2026: 185 · 2025: 242 · 2024: 302 · 2023: 382 · 2022: 377 · 2021: 438 · 2020: 361 · 2019: 288 · 2018: 223 · 2017: 31
- FWCI
- 108.88
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-01)
- Open access
- green
- europepmc.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (P30CA016672)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- nivolumab, metastatic colorectal cancer, mismatch repair deficiency, microsatellite instability-high, PD-1 inhibitors, immune checkpoint blockade, objective response rate, disease control rate, progression-free survival, overall survival, treatment toxicity, first-line therapy, second-line therapy, third-line therapy, neoantigens, tumor-infiltrating lymphocytes
- MeSH terms
- Nivolumab, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Microsatellite Instability, DNA Mismatch Repair, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
